Format

Send to

Choose Destination
See comment in PubMed Commons below
Mol Genet Metab. 2017 Jan - Feb;120(1-2):8-21. doi: 10.1016/j.ymgme.2016.11.006. Epub 2016 Nov 17.

Gaucher disease: Progress and ongoing challenges.

Author information

1
Yale University School of Medicine, Department of Internal Medicine, 333 Cedar Street, LMP 1080, P.O. Box 208019, New Haven, CT 06520-8019, United States. Electronic address: Pramod.mistry@yale.edu.
2
Medical Genetics Branch, NHGRI, NIH, Bldg 35A Room 1E623, 35 Convent Drive, Bethesda, MD 20892, United States. Electronic address: glopez@mail.nih.gov.
3
Institute of Metabolic Disease, Baylor Research Institute, Dallas, TX 75226, United States. Electronic address: Raphael.Schiffmann@BSWHealth.org.
4
Therapeutic Area Head Neuroscience, Shire plc, 300 Shire Way, Lexington, MA 02421, United States. Electronic address: nbarton@shire.com.
5
University of Miami Miller School of Medicine, Department of Human Genetics and Medicine (Hematology), UHealth Sylvester Coral Springs, 8170 Royal Palm Boulevard, Coral Springs, FL 33065, United States. Electronic address: boneal@winning.com.
6
Medical Genetics Branch, NHGRI, NIH, Bldg 35A Room 1E623, 35 Convent Drive, Bethesda, MD 20892, United States. Electronic address: sidranse@mail.nih.gov.

Abstract

Over the past decades, tremendous progress has been made in the field of Gaucher disease, the inherited deficiency of the lysosomal enzyme glucocerebrosidase. Many of the colossal achievements took place during the course of the sixty-year tenure of Dr. Roscoe Brady at the National Institutes of Health. These include the recognition of the enzymatic defect involved, the isolation and characterization of the protein, the localization and characterization of the gene and its nearby pseudogene, as well as the identification of the first mutant alleles in patients. The first treatment for Gaucher disease, enzyme replacement therapy, was conceived of, developed and tested at the Clinical Center of the National Institutes of Health. Advances including recombinant production of the enzyme, the development of mouse models, pioneering gene therapy experiments, high throughput screens of small molecules and the generation of induced pluripotent stem cell models have all helped to catapult research in Gaucher disease into the twenty-first century. The appreciation that mutations in the glucocerebrosidase gene are an important risk factor for parkinsonism further expands the impact of this work. However, major challenges still remain, some of which are described here, that will provide opportunities, excitement and discovery for the next generations of Gaucher investigators.

KEYWORDS:

Dr. Roscoe Brady; Enzyme replacement therapy; Gaucher disease; Glucocerebrosidase; Lysosomal storage disorder; Parkinsonism

PMID:
27916601
PMCID:
PMC5425955
[Available on 2018-01-01]
DOI:
10.1016/j.ymgme.2016.11.006
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center